Episode Details
Back to Episodes
After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of Replimune walks us through the program's timeline and history, and what this might mean for its future
Published 1 year, 1 month ago
Description
CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives Replimune's impression of how the review went since the BLA was filed last November, and he discusses what the CRL could mean for the future.